Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458943 | 0.80 | RECQL (0.46) | HPGDHSD17B10ALDH1A1GAAMEN1 | |
| SCHEMBL1525473 | 0.80 | HPGD (0.53) | HPGDMAPK1ALDH1A1MAPTKMT2A | |
| SCHEMBL6835272 | 0.77 | GRM5 (0.48) | HPGDPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL6640482 | 0.77 | PKM (0.66) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL22702163 | 0.77 | PKM (0.66) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL29457007 | 0.77 | PKM (0.66) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL9763711 | 0.76 | PKM (0.74) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL29944134 | 0.76 | ALDH1A1 (0.67) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL28324495 | 0.76 | ALDH1A1 (0.67) | HPGDPOLBPKMMAPK1ALDH1A1 | |
| SCHEMBL1569994 | 0.76 | ALDH1A1 (0.67) | HPGDPOLBPKMMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073728-A | Compounds and their use for modulating hemoglobin | GLOBAL BLOOD THERAPEUTICS INC | 2015-11-18 | — | — | CN | disclosed |
| CN-102229605-B | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALY SRL | 2015-01-14 | — | — | CN | disclosed |
| CN-104003979-A | Benzimidazole-2-piperazine compound, pharmaceutical composition of compound and preparing method and application of pharmaceutical composition | SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD | 2014-08-27 | — | — | CN | disclosed |
| CN-102219750-B | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ANGELETTI P IST RICHERCHE BIO | 2013-05-29 | — | — | CN | disclosed |
| EP-2144875-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144874-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008141011-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008137609-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | HPGD 81/4885POLB 1953/4885HSD17B10 572/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | HPGD 81/4885POLB 1953/4885HSD17B10 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.